Oncology Institute (STLN) Stock Price, News & Analysis

Company Overview

The Oncology Institute, Inc. is a healthcare services company focused on delivering value-based cancer care. The company works with oncologists, health plans and other healthcare organizations to coordinate treatment and manage the costs of oncology services while emphasizing quality, access and patient outcomes.

Its services include medical oncology and hematology care, cancer diagnosis and treatment planning, chemotherapy and infusion services, supportive care, clinical research and care-management programs. The Oncology Institute also uses data and clinical protocols to help physicians coordinate care across the cancer-treatment journey and reduce avoidable hospitalizations and other unnecessary costs.

The company was established to expand access to community-based oncology care and has historically operated through a network of affiliated physicians and outpatient care centers, primarily serving patients in the United States. Its care model is designed to provide treatment closer to patients’ homes while supporting collaboration among oncologists, primary-care providers and health plans.

Key Stats

• Today's Range: $6.52 to $7.00
• 50-Day Range: N/A
• 52-Week Range: $2.32 to $7.05
• Volume: 1.21 million shs
• Average Volume: 1.81 million shs
• Market Capitalization: $662.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncology Institute has a consensus price target of $8.50, representing about 25.0% upside from its current price of $6.80.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncology Institute are expected to grow in the coming year, from ($0.21) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncology Institute is -22.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.21% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 5.58.

Change versus previous month

Short interest in Oncology Institute has recently decreased by 0.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.20

News Sentiment

Oncology Institute has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Oncology Institute this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for STLN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

7 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have sold 453.57% more of their company's stock than they have bought. Specifically, they have bought $351,450.00 in company stock and sold $1,945,533.00 in company stock.

Percentage Held by Insiders

4.40% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

36.86% of the stock of Oncology Institute is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:STLN
• Previous Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: www.starlingoncology.com
• Phone: (562) 735-3226
• Fax: N/A
• Employees: 641
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncology Institute: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +26.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.61 million
• Net Margins: -6.18%
• Pretax Margin: -6.18%
• Return on Equity: N/A
• Return on Assets: -21.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.36
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $502.73 million
• Price / Sales: 1.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.16) per share
• Price / Book: -42.16

Miscellaneous

• Outstanding Shares: 98,840,000
• Free Float: 94,490,000
• Market Cap: $666.68 million
• Optionable: N/A
• Beta: 0.41